Oncosil Medical Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Key Metrics
PE ratio
-
PB ratio
3.26
Dividend yield
-
Beta
1.23
Market cap
$13.41M
Enterprise value
$5.06M
Company profile
| Industry / Sector | Medical Devices / Healthcare |
|---|---|
| Website | https://www.oncosil.com |
| Mailing address | 7 Eden Park Drive Level 5 Macquarie Park NSW 2113 Australia |
| Phone / Fax | 61 2 8935 9629 / |
Dividends
More: Oncosil Medical Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Oncosil Medical paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.OSL dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Oncosil Medical.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Nigel Lange | CEO, MD & Director | ||
| Ms. Shelley Steyn | Chief Financial Officer | ||
| Mr. David Turner | Head of Medical Affairs | ||
| Mr. David Wood | Joint Company Secretary | ||
| Mr. Timothy Luscombe B.Com., C.A. | Joint Company Secretary |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-1530.10%
Return on assets
-136.02%
Return on equity
-385.20%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Oncosil Medical is 13.41M and its enterprise value is 5.06M. The enterprise value to revenue ratio of OSL is 3.29. The enterprise value to EBITDA ratio of OSL is -0.34.
The OSL's stocks Beta value is 1.23 making it 23% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Oncosil Medical (OSL)
Oncosil Medical (ASX:OSL) Frequently Asked Questions
1. What is Oncosil Medical's Stock Symbol?
Oncosil Medical trades on ASX under the ticker symbol "OSL".
2. What is Oncosil Medical's stock price today?
One share of OSL stock can currently be purchased for approximately $0.71.
3. How can I contact Oncosil Medical?
Oncosil Medical's mailing address is 7 Eden Park Drive Level 5 Macquarie Park NSW 2113 Australia. The company can be reached via phone at 61 2 8935 9629.
4. What is Oncosil Medical's official website?
The official website of Oncosil Medical is https://www.oncosil.com.